We analyzed microarray-derived expression data acquired from dissected sympathetic ganglia from hyperplastic lesions at week 2 and tumor tissue at week 6 from the Tyrosine hydroxylase (TH)–MYCN–driven neuroblastoma mouse model presented by De Wyn et al. (41) and found that MOXD1 expression steadily decreases with tumor progression (Fig. 3A). This evidence concerns the gene MYCN and neoplasm.